Equity Profile

DNTH

Dianthus Therapeutics, Inc.

Health CareBiotechnology$5.4B

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Dianthus Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for serious diseases....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and financial health.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and drive sales.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

DNTH Q2-2026 Earnings Preview

Context

Company Snapshot

Dianthus Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for serious diseases. With a market cap of $5 billion, it operates within the health care sector, which is increasingly vital as the demand for advanced medical treatments grows.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

-6.28%

Avg Stock Reaction

+2.74%

Last Quarter Recap

In the last quarter (Q1-2026), Dianthus reported an EPS of -$0.85, which was better than the expected -$1.17, resulting in a positive surprise. The stock saw a modest increase of 1.01% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall expectations are mixed as analysts await clearer guidance on revenue and profitability. The stock has shown volatility in response to earnings surprises in the past.

Bull Case

If Dianthus can demonstrate significant progress in its drug development pipeline, it may attract more investor interest and drive the stock price higher.

Bear Case

Conversely, if the company fails to meet expectations on revenue or shows delays in its clinical trials, it could lead to a decline in stock value.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

The EPS figure will be crucial in assessing the company's financial health and could significantly impact investor sentiment.

What updates can management provide on the drug development pipeline?

Any delays or advancements in the pipeline could influence future revenue potential and investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for Dianthus to exceed EPS expectations based on recent positive developments in its drug pipeline.

Supporting Evidence

The company has shown a pattern of beating EPS estimates in recent quarters.

Options pricing suggests a significant move, indicating that traders expect volatility that may not align with consensus.

The historical trend shows that the stock often reacts positively to earnings surprises, even when missing estimates.

Key Risk

If the EPS comes in better than expected, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core thesis revolves around the company's ability to improve profitability and advance its drug pipeline, which are critical for future growth.

Bull Confirmed If

A positive EPS surprise of at least $0.10 would confirm the bull case.

Bear Confirmed If

An EPS below -$1.00 would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±23.01%

Historical Avg

±5.2%

Pricing rich

The options market is pricing in a significant move, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±23.0% while DNTH has averaged ±5.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

38.6%

Calls (5K)P/C Ratio: 0.19Puts (2K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Dianthus beats expectations, history suggests a potential stock increase of around 1% on the first day, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further clarity on future guidance.

Miss

A miss could lead to a decline of approximately 4.47%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the status of ongoing clinical trials.
2Management's outlook on revenue growth for the upcoming quarters.
3Details on any new partnerships or collaborations.
4Insights into cost management and operational efficiency.
5Comments on competitive positioning within the biotechnology sector.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Danaos Corporation

Company Snapshot

Dianthus Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for serious diseases....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and financial health.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and drive sales.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

DNTH Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

-6.28%

Avg Stock Reaction

+2.74%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall expectations are mixed as analysts await clearer guidance on revenue and profitability. The stock has shown volatility in response to earnings surprises in the past.

Bull Case

If Dianthus can demonstrate significant progress in its drug development pipeline, it may attract more investor interest and drive the stock price higher.

Bear Case

Conversely, if the company fails to meet expectations on revenue or shows delays in its clinical trials, it could lead to a decline in stock value.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

The EPS figure will be crucial in assessing the company's financial health and could significantly impact investor sentiment.

What updates can management provide on the drug development pipeline?

Any delays or advancements in the pipeline could influence future revenue potential and investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for Dianthus to exceed EPS expectations based on recent positive developments in its drug pipeline.

Supporting Evidence

The company has shown a pattern of beating EPS estimates in recent quarters.

Options pricing suggests a significant move, indicating that traders expect volatility that may not align with consensus.

The historical trend shows that the stock often reacts positively to earnings surprises, even when missing estimates.

Key Risk

If the EPS comes in better than expected, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core thesis revolves around the company's ability to improve profitability and advance its drug pipeline, which are critical for future growth.

Bull Confirmed If

A positive EPS surprise of at least $0.10 would confirm the bull case.

Bear Confirmed If

An EPS below -$1.00 would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±23.01%

Historical Avg

±5.2%

Pricing rich

The options market is pricing in a significant move, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±23.0% while DNTH has averaged ±5.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

38.6%

Calls (5K)P/C Ratio: 0.19Puts (2K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Dianthus beats expectations, history suggests a potential stock increase of around 1% on the first day, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further clarity on future guidance.

Miss

A miss could lead to a decline of approximately 4.47%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the status of ongoing clinical trials.
2Management's outlook on revenue growth for the upcoming quarters.
3Details on any new partnerships or collaborations.
4Insights into cost management and operational efficiency.
5Comments on competitive positioning within the biotechnology sector.